PDUFA funds sought for postmarketing reviews, Public Citizen's Wolfe testifies at Senate hearing.
USER FEE FUNDING OF POSTMARKETING REVIEWS SOUGHT BY PUBLIC CITIZEN's Health Research Group to address the growing workload at FDA's Division of Drug Marketing, Advertising & Communications, according to the testimony of HRG Director Sidney Wolfe, MD, at an April 11 hearing of the Senate Labor & Human Resources Committee. Wolfe noted that the number of drug launch campaigns jumped from 118 in FY 1993 to over 300 in FY 1996. During that same interval, the number of notice of violation letters issued by DDMAC dropped from 247 to 137. Wolfe attributed the decline in NOV letters to a static staffing level at DDMAC.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth